NEWARK, Del. and NANJING, China, March 21, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage b...
- First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel anti...
NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a globa...
NEWARK, Del. and NANJING, China, July 5, 2023 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global, ...
NEWARK, Del. and NANJING, China, May 8, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global ...
NEWARK, Del. and NANJING, China, April 4, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a globa...
NEWARK, Del., March 22, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnolog...
Collaboration to explore potential of creating next-generation antibody-drug conjugateswith Biosion...
NEWARK, Del., Sept. 7, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global R&D biotechnology ...
NEWARK, Del. and NANJING, China, Aug. 22, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a leadin...
- Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referre...
NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global ...
NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global c...